Efficacy and cytotoxicity of cationic‐agent–mediated nonviral gene transfer into osteoblasts
- 15 September 2004
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 71A (2) , 308-315
- https://doi.org/10.1002/jbm.a.30160
Abstract
Ex vivo gene transfer into osteoblastic cells is an advantageous strategy for bone tissue engineering. This study investigated the efficacy and cytotoxicity of in vitro cationic-agent–mediated nonviral gene transfer into osteoblasts. Various cationic agents, lipid, gelatin, and polyethylenimine (PEI) were tested. Each was formulated in various concentrations to form a complex with plasmid DNA encoding red fluorescent protein. The cationic agent/DNA complexes were transfected into human fetal osteoblastic cell line and rat bone-marrow–derived primary osteoblasts, as well as NIH 3T3 fibroblast controls. Rat primary osteoblasts were transfected more with cationic lipid and PEI agents than with gelatin carrier, yielding transfection efficacy up to 18.1% and 12.7 %, respectively. In contrast, human fetal osteoblastic cell line was transfected more with cationic lipid and gelatin than with PEI. There was a positive correlation between the lipid and PEI doses and cytotoxicity. When the lipid and PEI were used to transfect the rat primary osteoblasts in a dose that yielded the highest transfection efficacy, cell survival rates decreased as low as 40%. When their transfection efficacies into primary osteoblasts were compromised at two thirds of the highest value, that is, 12.6% and 8.3% for the lipid and PEI, respectively, the cell survival rate was nearly 80%. Cationic gelatin was associated with cell survival rates over 60 % in any cell type, regardless of the doses tested. These results suggest that different types of osteoblastic cells may possess different ability to the uptake and expression of cationic-agent–bound DNA. There seemed to be agent-specific threshold doses that dropped the cell survival rate. Cationic-agent–mediated nonviral gene transfer into osteoblastic cells may be successful when the agent- and dose-dependent transfection efficacy and cytotoxicity are optimized. © 2004 Wiley Periodicals, Inc. J Biomed Mater Res 71A: 308–315, 2004Keywords
This publication has 41 references indexed in Scilit:
- Synergistic enhancement of bone formation and healing by stem cell–expressed VEGF and bone morphogenetic protein-4Journal of Clinical Investigation, 2002
- In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vectorCancer Gene Therapy, 2002
- Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in ratsGene Therapy, 2002
- Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cellsNature Biotechnology, 2002
- Transgene Expression in the Brain Stem Effected by Intramuscular Injection of Polyethylenimine/DNA ComplexesMolecular Therapy, 2001
- Osteoinductive Applications of Regional Gene TherapyClinical Orthopaedics and Related Research, 2000
- Impact of pharmacodynamic variability on drug delivery1Advanced Drug Delivery Reviews, 1998
- Gene therapy for tissue repair and regenerationAdvanced Drug Delivery Reviews, 1998
- High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid–DNA complexGene Therapy, 1997
- Tissue EngineeringScience, 1993